SEC Form 4 · accession 0001104659-26-105506
Addex Therapeutics Ltd. · ADXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mikhail Kalinichev
Officer — HEAD OF TRANSLATIONAL SCIENCE
Period of report
Sep 2, 2026
Accepted (ET)
Sep 4, 2026 · 4:09 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001574232
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 2, 2026 | D | 306,765 | $0.00 | D | 0 | D | |
| Common StockF1 | Sep 2, 2026 | A | 306,765 | $0.00 | A | 306,765 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-option (Right to Buy)F3 | $0.062 | Sep 2, 2026 | D | 200,000 | D | Jan 8, 2024 | Jan 7, 2034 | Common Stock | 200,000 | 0 | D |
| Stock-option (Right to Buy)F3 | $0.032 | Sep 2, 2026 | A | 200,000 | A | Jan 8, 2024 | Jan 7, 2034 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1Represents 306,765 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 179,171 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 127,594 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $ 1.2296 per CHF 1.00 as of September 2, 2026.
- F2On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
- F3The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.